挪威非转移性前列腺癌男性十年死亡率研究
基于挪威前列腺癌登记处2004-2005年确诊的3449例非转移性前列腺癌患者,计算10年前列腺癌特异性死亡率(PCSM)和总死亡率(OM)。10年PCSM为8.5%(根治性前列腺切除术1.5%、放疗6.2%、未局部治疗16.3%),OM为25.5%。结果支持在高危患者中增加局部治疗的使用,并建议将Gleason分级分组(GGG)应用于临床实践。
要点
- 10年PCSM为8.5%,根治性前列腺切除术1.5%、放疗6.2%、未局部治疗16.3%。
- 10年OM为25.5%,约为PCSM的3倍,低危组差异最大、高危组最小。
- ECOG体能状态≥1分者PCSM风险是0分者的2倍。
核心结论
- 所有患者10年OM约为PCSM的3倍,低危和高危肿瘤患者差异分别最大和最小。
- 结果支持在高危患者中增加局部治疗的使用。
- GGG应应用于临床实践;ECOG体能状态作为预后因素的作用需在未来研究中验证。
研究设计与样本
- 基于挪威前列腺癌登记处的数据,纳入2004-2005年确诊的非转移性前列腺癌患者3449例。
- 患者接受根治性前列腺切除术(n=913)、放疗(n=1334)或未局部治疗(n=1202)。
- 按风险组、Gleason分级分组(GGG)和东部肿瘤协作组(ECOG)体能状态分层,采用Aalen-Johansen和Kaplan-Meier估计及比例风险回归分析。
主要发现
- 10年PCSM率为8.5%(根治性前列腺切除术1.5%、放疗6.2%、未局部治疗16.3%),OM率为25.5%。
- 低危组中死于其他原因的风险较死于前列腺癌增加8倍,高危患者中相应倍数约为2。
- 高危因素患者似乎从局部治疗中获益最大;每个风险组内5个GGG均改善PCSM预测。
- ECOG体能状态≥1分者PCSM风险是ECOG 0分者的2倍。
关键数值与推荐
- 10年PCSM率8.5%,OM率25.5%。
- 根治性前列腺切除术10年PCSM 1.5%,放疗6.2%,未局部治疗16.3%。
- 低危组死于其他原因风险为死于前列腺癌的8倍,高危组约为2倍。
- ECOG体能状态≥1分者PCSM风险为ECOG 0分者的2倍。
临床怎么用
- 结果支持在高危患者中增加局部治疗的使用。
- GGG应应用于临床实践。
- ECOG体能状态作为预后因素的作用需在未来研究中验证。
局限性
- ECOG体能状态作为预后因素的作用需在未来研究中验证。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVE: To provide population-based data on 10-year prostate cancer-specific mortality (PCSM), overall mortality (OM), treatment, and prognostic factors in patients with nonmetastatic prostate cancer (PCa). MATERIALS AND METHODS: Based on data from the Norwegian Prostate Cancer Registry, we calculated 10-year PCSM and OM in 3449 patients diagnosed with nonmetastatic PCa in 2004-2005 who underwent radical prostatectomy (n = 913), radiotherapy (n = 1334), or no local treatment (n = 1202). Patients were stratified according to risk group, Gleason grade group (GGG), and Eastern Cooperative Oncology Group (ECOG) performance status. Aalen-Johansen and Kaplan-Meier estimates and proportional hazards regressions were used. RESULTS: The 10-year PCSM rate was 8.5% (radical prostatectomy: 1.5, radiotherapy: 6.2%, no local treatment: 16.3%) and the OM rate was 25.5%. In the low-risk group, the risk of dying from other causes was 8-fold increased compared with death from PCa, the comparable factor being approximately 2 among high-risk patients. Patients with high-risk factors seemed to benefit the most from local treatment. Within each risk group, the 5 GGGs improved the prediction of PCSM. Having an ECOG performance status of ≥1 doubled the risk of PCSM compared with patients with an ECOG performance status of 0. CONCLUSION: For all patients, the 10-year OM was about 3 times higher than PCSM, the greatest and lowest discrepancies emerging among patients with low- and high-risk tumors, respectively. The results support increased use of local treatment in high-risk patients. GGGs should be implemented in clinical practice. The role of ECOG performance status as prognostic factor has to be validated in future studies.
引用
- Aas K, Axcrona K, Kvåle R, et al. Ten-year Mortality in Men With Nonmetastatic Prostate Cancer in Norway. Urology. 2017. PMID: 28823634. doi:10.1016/j.urology.2017.07.048
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。